Stock Scorecard



Stock Summary for Laboratory Corp Of America Holdings (LH) - $284.00 as of 10/24/2025 5:39:55 PM EST

Total Score

14 out of 30

Safety Score

61 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for LH

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LH

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LH

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LH

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LH (61 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 7
Book Value (Max of 10) 10
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 1
Operating Margin (Max of 10) 3
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 5
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for LH

Healthcare Analytical Testing Services Market is expected to generate a revenue of USD 9.56 Billion by 2031, Globally, at 11.20% CAGR: Verified Market Research® 7/31/2025 2:00:00 PM
Labcorp Posts 9.5 Percent Gain in Q2 7/24/2025 10:12:00 PM
Here's Why You Should Retain OPKO Health Stock in Your Portfolio 6/13/2025 4:37:00 PM
Genomics Market to Hit US$66.8 Billion by 2029 with 9.4% CAGR | MarketsandMarkets™. 6/11/2025 12:30:00 PM
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts 3/24/2025 8:05:00 PM
Organ Transplant Diagnostics Market Size to Surpass USD 12.57 Billion by 2033 | Straits Research 1/29/2025 1:25:00 PM
Here's Why You Should Retain OPKO Health Stock in Your Portfolio 1/9/2025 12:53:00 PM
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer - OncoCyte ( NASDAQ:OCX ) 1/8/2025 1:30:00 PM
Healthcare Analytical Testing Services Market to Surpass Valuation of USD 15.55 Billion by 2031 | SkyQuest Technology 12/16/2024 1:00:00 AM
Cell-Free DNA Mutation Diagnostics Market to Surge to US$ 81,584.2 Million by 2034, Growing at a CAGR of 24.9% | Fact.MR Report 12/5/2024 11:00:00 AM

Financial Details for LH

Company Overview

Ticker LH
Company Name Laboratory Corp Of America Holdings
Country USA
Description Laboratory Corporation of America Holdings (Labcorp), headquartered in Burlington, North Carolina, is a leading global life sciences company that provides comprehensive laboratory services and solutions essential for healthcare advancement. With a robust network of 36 clinical laboratories across the United States, Labcorp delivers a wide array of diagnostic testing and drug development services, playing a pivotal role in enhancing patient care. By harnessing cutting-edge technology and sophisticated data analytics, the company is at the forefront of personalized medicine, positioning itself as an indispensable partner in improving health outcomes worldwide.
Sector Name HEALTHCARE
Industry Name DIAGNOSTICS & RESEARCH
Most Recent Quarter 6/30/2025
Next Earnings Date 10/23/2025

Stock Price History

Last Day Price 284.00
Price 4 Years Ago 258.49
Last Day Price Updated 10/24/2025 5:39:55 PM EST
Last Day Volume 522,477
Average Daily Volume 530,672
52-Week High 293.72
52-Week Low 208.23
Last Price to 52 Week Low 36.39%

Valuation Measures

Trailing PE 31.36
Industry PE 43.15
Sector PE 41.12
5-Year Average PE 17.02
Free Cash Flow Ratio 36.46
Industry Free Cash Flow Ratio 98.26
Sector Free Cash Flow Ratio 31.25
Current Ratio Most Recent Quarter 1.50
Total Cash Per Share 7.79
Book Value Per Share Most Recent Quarter 102.20
Price to Book Ratio 2.74
Industry Price to Book Ratio 244.81
Sector Price to Book Ratio 32.29
Price to Sales Ratio Twelve Trailing Months 1.76
Industry Price to Sales Ratio Twelve Trailing Months 4.77
Sector Price to Sales Ratio Twelve Trailing Months 16.43
Analyst Buy Ratings 12
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 83,100,000
Market Capitalization 23,600,400,000
Institutional Ownership 100.19%

Dividends

Ex-Dividend Date 11/26/2025
Previous Dividend Amount 0.7200
Current Dividend Amount 0.7200
Total Years Dividend Increasing 0
Trailing Annual Dividend Rate 2.88
Trailing Annual Dividend Yield 1.01%
Forward Annual Dividend Rate 2.88
Forward Annual Dividend Yield 1.01%
5-Year Dividend Payments Count 15
3-Year Average Dividend Yield 1.28%
5-Year Average Dividend Yield 1.28%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 31.95%
All-Time Dividend Growth Rate Percentage 31.95%
Dividend Payout Ratio 31.79%

Income Statement

Quarterly Earnings Growth YOY 16.90%
Annual Earnings Growth 78.47%
Reported EPS 12 Trailing Months 9.06
Reported EPS Past Year 8.19
Reported EPS Prior Year 14.57
Net Income Twelve Trailing Months 763,400,000
Net Income Past Year 746,000,000
Net Income Prior Year 418,000,000
Quarterly Revenue Growth YOY 9.50%
5-Year Revenue Growth 2.40%
Operating Margin Twelve Trailing Months 11.30%

Balance Sheet

Total Cash Most Recent Quarter 647,300,000
Total Cash Past Year 1,518,700,000
Total Cash Prior Year 536,800,000
Net Cash Position Most Recent Quarter -4,430,000,000
Net Cash Position Past Year -3,812,500,000
Long Term Debt Past Year 5,331,200,000
Long Term Debt Prior Year 4,054,700,000
Total Debt Most Recent Quarter 5,077,300,000
Equity to Debt Ratio Past Year 0.60
Equity to Debt Ratio Most Recent Quarter 0.63
Total Stockholder Equity Past Year 8,052,200,000
Total Stockholder Equity Prior Year 7,875,000,000
Total Stockholder Equity Most Recent Quarter 8,472,700,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 1,261,800,000
Free Cash Flow Per Share Twelve Trailing Months 15.18
Free Cash Flow Past Year 1,095,900,000
Free Cash Flow Prior Year 874,100,000

Options

Put/Call Ratio 2.92
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 2.69
MACD Signal 1.70
20-Day Bollinger Lower Band 246.51
20-Day Bollinger Middle Band 269.48
20-Day Bollinger Upper Band 292.44
Beta 0.87
RSI 69.15
50-Day SMA 249.19
150-Day SMA 219.59
200-Day SMA 216.25

System

Modified 10/23/2025 3:31:34 AM EST